232 related articles for article (PubMed ID: 6223205)
1. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
Sibley DR; Creese I
Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
[TBL] [Abstract][Full Text] [Related]
2. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
Leff SE; Creese I
Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
[TBL] [Abstract][Full Text] [Related]
3. Correlation of alpha- and beta-rotameric forms of 2-substituted octahydrobenzo[f]quinoline dopamine congeners with high and low affinity states of the anterior pituitary dopamine receptor and prolactin inhibition.
Findell PR; Torkelson SM; Craig JC; Weiner RI
Mol Pharmacol; 1988 Jan; 33(1):78-83. PubMed ID: 3336350
[TBL] [Abstract][Full Text] [Related]
4. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor.
Sibley DR; De Lean A; Creese I
J Biol Chem; 1982 Jun; 257(11):6351-61. PubMed ID: 6176582
[TBL] [Abstract][Full Text] [Related]
5. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
Gundlach AL; Krstich M; Beart PM
Brain Res; 1983 Nov; 278(1-2):155-63. PubMed ID: 6227373
[TBL] [Abstract][Full Text] [Related]
6. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland.
Wreggett KA; De Léan A
Mol Pharmacol; 1984 Sep; 26(2):214-27. PubMed ID: 6237254
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
Enjalbert A; Bockaert J
Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic activity of some ergot alkaloid derivatives: relationship to their chemical structure.
Soskić V; Petrović J; Trajković D; Kidric M
Pharmacology; 1986; 32(3):157-66. PubMed ID: 2938196
[TBL] [Abstract][Full Text] [Related]
9. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.
Munemura M; Agui T; Sibley DR
Endocrinology; 1989 Jan; 124(1):346-55. PubMed ID: 2521206
[TBL] [Abstract][Full Text] [Related]
10. Agonist high- and low-affinity states of the D2-dopamine receptor in calf brain. Partial conversion by guanine nucleotide.
Wreggett KA; Seeman P
Mol Pharmacol; 1984 Jan; 25(1):10-7. PubMed ID: 6231467
[TBL] [Abstract][Full Text] [Related]
11. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
Hamblin MW; Creese I
Mol Pharmacol; 1982 Jan; 21(1):44-51. PubMed ID: 6127621
[TBL] [Abstract][Full Text] [Related]
12. Characterization of D-2 dopamine receptors in a tumor of the rat anterior pituitary gland.
Lin C; McGonigle P; Molinoff PB
J Pharmacol Exp Ther; 1987 Sep; 242(3):950-6. PubMed ID: 2958621
[TBL] [Abstract][Full Text] [Related]
13. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.
Leff SE; Hamblin MW; Creese I
Mol Pharmacol; 1985 Feb; 27(2):171-83. PubMed ID: 3969066
[TBL] [Abstract][Full Text] [Related]
14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states.
George SR; Watanabe M; Seeman P
J Neurochem; 1985 Apr; 44(4):1168-77. PubMed ID: 2579204
[TBL] [Abstract][Full Text] [Related]
16. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
17. D-2 dopamine receptors in aging mouse striatum: determination of high- and low-affinity agonist binding sites.
Severson JA; Randall PK
J Pharmacol Exp Ther; 1985 May; 233(2):361-8. PubMed ID: 3158731
[TBL] [Abstract][Full Text] [Related]
18. Agonist interactions with dopamine receptors: focus on radioligand-binding studies.
Creese I; Sibley DR; Leff SE
Fed Proc; 1984 Oct; 43(13):2779-84. PubMed ID: 6383871
[TBL] [Abstract][Full Text] [Related]
19. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
Goldstein M; Lew JY; Hata F; Lieberman A
Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
Oda T; Kume T; Izumi Y; Takada-Takatori Y; Niidome T; Akaike A
Eur J Pharmacol; 2008 Nov; 598(1-3):27-31. PubMed ID: 18835264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
